← Leaderboards
Lynn M Hassman
University Of Virginia
$1,004,715
Attributed
$1,004,715
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $218.7K · FY2009–25$250K$187.5K$125K$62.5K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,004,715 · 2
By mechanism
K08$873,954 · 1
F30$130,761 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Manoj K Patel$7,822,105
- Ling Qi$16,888,448
- Melissa S Anderson$85,929
- Evonne N Woodson$84,648
- Brett Ransegnola$76,960
Others in their field
Top investigators on “Therapeutic Target”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$399,079,477
- Judith S. Currier · University Of California Los Angeles$274,271,371
- Peter C Adamson · National Childhood Cancer Foundation$268,343,924
- Barbara Driver · Westat, Inc.$175,154,472
Research focus
Therapeutic TargetSignal TransductionInvestigationIn VitroCellsInsightPhenotypeIn VivoGene ExpressionAcuteB Cell ProliferationB-Cell ActivationBioinformaticsBiological MarkersAdoptedCell MotilityAffectB-Lymphocyte SubsetsB-LymphocytesAutomobile DrivingCancer TypeCandidate Disease GeneCandidate MarkerAdaptive Immune Response
Grant awards (8)
Resolution of ocular inflammation: the role of type 1 conventional dendritic cells$218,737
K08 · FY2025 · EY · contact PI
Resolution of ocular inflammation: the role of type 1 conventional dendritic cells$218,737
K08 · FY2024 · EY · contact PI
Resolution of ocular inflammation: the role of type 1 conventional dendritic cells$218,240
K08 · FY2023 · EY · contact PI
Resolution of ocular inflammation: the role of type 1 conventional dendritic cells$218,240
K08 · FY2022 · EY · contact PI
Infection of primary B cells by the human lymphomagenic pathogen HHV8$7,608
F30 · FY2012 · HL · contact PI
Infection of primary B cells by the human lymphomagenic pathogen HHV8$46,800
F30 · FY2011 · HL · contact PI
Infection of primary B cells by the human lymphomagenic pathogen HHV8$48,717
F30 · FY2010 · HL · contact PI
Infection of primary B cells by the human lymphomagenic pathogen HHV8$27,636
F30 · FY2009 · HL · contact PI